DOCSLIB.ORG

Cancer Chemotherapy Reviews

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cancer Chemotherapy Reviews Cancer Chemotherapy& Reviews Volume 16 - Number 2 • April-June 2021 • Published quarterly • ISSN: 1885-740X http://www.cancerchemotherapyreviews.com Indexed in EMBASE/Excerpta Medica Clinical situations in which platinum is not the treatment of choice for ovarian cancer patients who relapse beyond 6 months Coordinated by Domenica Lorusso CLINICAL CASES Wild-type patient unable to receive bevacizumab in first-line who relapsed between 6 and 12 months Claudia Andreetta 19 BRCA mutated patient consecutively treated with bevacizumab, PARP inhibitors and trabectedin + PLD as first, second, and third line Valentina Arcangeli 25 Heavily pre-treated BRCA-mutated patient who relapsed between 6 and 12 months during fourth-line therapy Viviana Murgia 33 A scientific initiative of the ECO Foundation PERMANYER www.permanyer.com Cancer Editor-in-Chief & Eduardo Díaz-Rubio Madrid, Spain Chemotherapy Editor Reviews Pedro Pérez-Segura Madrid, Spain Volume 16 - Number 2 • April-June 2021 • Published quarterly • ISSN: 1885-740X http://www.cancerchemotherapyreviews.com Indexed in EMBASE/Excerpta Medica Editorial Board Matti S. Aapro Hernán Cortés-Funes Arthur Katz Luis Paz-Ares Switzerland Spain Brazil Spain Albert Abad-Esteve Juan Jesús Cruz-Hernández David Kerr Gumersindo Pérez-Manga Spain Spain UK Spain Emilio Alba-Conejo Javier Dorta Paris A. Kosmidis Josep Manuel Piera-Pibernat Spain Spain Greece Spain Joan Albanell Enriqueta Felip Roberto Labianca Rafael Rosell Spain Spain Italy Spain Antonio Antón-Torres Spain Pilar García-Alfonso Thierry Le Chevalier Antonio Rueda Spain France Spain Enrique Aranda-Aguilar Spain Jesús García-Foncillas López Rafael López-López Jesús San Miguel Spain Spain Spain Agustin Barnadas Spain José Luis García-Puche Guillermo López-Vivanco José Sánchez de Toledo Norberto Batista Spain Spain Spain Spain Pilar Garrido-López Ana Lluch-Hernández Jaime Sanz-Ortiz Manuel Benavides-Orgaz Spain Spain Spain Spain Pere Gascón-Vilaplana Salvador Martín-Algarra Hans Schmoll Carlos Camps-Herrero Spain Spain Germany Spain Vicente Guillem-Porta Miguel Martín-Jiménez Jorge Soriano-García Alfredo Carrato-Mena Spain Spain Cuba Spain José Ramón Germà-Lluch Michel Marty Josep Tabernero Javier Cassinello-Espinosa Spain France Spain Spain Manuel Hidalgo Bartomeu Massuti Maurizio Tonato Eduardo Cazap USA Spain Italy Argentina Guadalupe Cervantes Paulo Hoff Emili Montserrat Laura Torrecillas Mexico Brazil Spain Mexico Manuel Codes de Villena Gabriel Hortobagyi José Andrés Moreno-Nogueira Eric Van Cutsem Spain USA Spain Belgium Ramón Colomer Carlos Jara-Sánchez Ignacio Muse Raúl Vera-Gimón Spain Spain Uruguay Venezuela Manuel Constenla-Figueras Ángel Jiménez-Lacave Carlos de Oliveira Daniel A. Vorobiof Spain Spain Portugal South Africa A scientific initiative of the ECO Foundation PERMANYER www.permanyer.com Annual Subscription Order Form to Cancer & Chemotherapy Reviews ISSN: 1885-740X Published quarterly Print edition Electronic edition Personal subscription: € 130.00 Personal subscription: € 100.00 Corporate subscription: € 230.00 Corporate IP subscription: (quotation without compromise, please contact [email protected] with information about quantity and type of IP’s) PAYMENT OPTIONS: I enclose a check made payable to P. Permanyer, S.L. I wish to pay by credit card: VISA MASTER CARD Card number: Expiry date: / Signature: Name (capitals): Address: Country: Postcode: Phone: Fax: E-mail: Send Orders to: For the purposes set forth in Organic Law 15/1999, on Personal Data Protection, we inform you that the personal data furnished in this bulletin shall be included in a filed created under the direction P. PERMANYER, S.L. of PUBLICIDAD PERMANYER, S.L., in order to fulfil your request for subscription. You have the right to access the information Subscription Department regarding yourself collected in our file, to correct the data if it Mallorca, 310 - 08037 Barcelona - Spain is incorrect or cancel it, as well as to oppose processing of such data at the following address: PUBLICIDAD PERMANYER S.L., Phone: +34 93 476 01 76 - Fax: +34 93 457 66 42 Mallorca 310, 08037 BARCELONA - Administration Department. E-mail: [email protected] Signed: The interested party Copyright © 2021 by P. Permanyer Mallorca, 310 - 08037 Barcelona (Catalonia), Spain Phone: +34 93 207 59 20 Fax: +34 93 457 66 42 ISSN: 1885-740X/2339-8728 • Legal deposit: B-47.879-2006 • Ref.: 6287AM201 Contact: PERMANYER [email protected] www.permanyer.com www.permanyer.com This paper meets the requirements of ANSI/NISO Printed on acid-free paper Z39.48-1992 (Permanence of paper) All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronically, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher. All the information provided and opinions expressed have not involved any verification of the findings, conclusions, and opinions by Editors and Publishers. No responsi- bility is assumed by Publisher for any injury and/or damage to persons or property as result of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the publisher recommends that independent verification of diagnoses and drug dosages should be made. www.cancerchemotherapyreviews.com PERMANYER Cancer & Chemotherapy Rev. 2021;16:19-24 www.permanyer.com Wild-type patient unable to receive bevacizumab in first-line who relapsed between 6 and 12 months Claudia Andreetta Department of Oncology, Azienda Ospedaliera Universitaria, Udine Clinical summary 67-year-old patient; arterial hypertension, prior abdominal aortic aneurysm. June 2018: hysterectomy with bilateral salpingo-oophorectomy, peritoneal washing, lymphadenectomy, omentectomy, peritoneal biopsies. Residual tumor <1 cm. Histology: high-grade serous ovarian carcinoma, pT3cN1, FIGO stage: IIIC. No BRCA1/2 mutation. July 2018: first line with carboplatin AUC5 + paclitaxel 175 mg/m2 iv q21 - 6 cycles. Allergic reaction during last cycle. Bevacizumab was not administered due to the history of aortic aneurysm. July 2019: Peritoneal progression disease (PD) (progression free interval [PFI] 6-12 months). Second line with trabectedin + pegylated liposomal doxorubicin (PLD) for 6 cycles with stable disease (discontinued in accordance with patient's wishes). Reported toxicities: G1 asthenia, G1 nausea, G1 mucositis. REVIEWS Correspondence: CANCER &CHEMOTHERAPY Claudia Andreetta E-mail: [email protected] 19 CANCER & CHEMOTHERAPY Rev. 2021;16 History and clinical characterization + paclitaxel 175 mg/m2 iv q21 regimen, for 6 cycles. – 67-year-old woman in good health. – Carboplatin infusion-related reaction reported – Comorbidities: arterial hypertension, prior ab- during the last cycle, characterized by sweats, dominal aortic aneurysm (surgically corrected hypotension and rash, treated with steroids in 2013). and antihistamines. – Home therapy: ramipril 5 mg/day, acetylsali- – CA-125 normalized from the second cycle of cylic acid 100 mg/day, delorazepam 12 drops/ therapy. day. – CT scan of the chest and abdomen after the – In May 2018: patient complained of increase sixth cycle (December 10, 2018): no evidence in volume of the abdomen, feeling of gastric of residual disease. fullness, and dyspnea on slight exertion. – The patient’s general practitioner indicated During follow-up: first-level diagnostic investigations (abdominal – On 20/06/2019: CA-125 384 IU/mL. ultrasound and chest X-ray) and referred her – On 10/07/2019: Contrast-enhanced CT scan to a gynecology outpatient clinic following the of the chest and abdomen revealed multiple finding of peritoneal carcinomatosis and a nodules of carcinomatosis in all quadrants of suspicious ovarian mass. the abdomen. – Following the gynecology consultation and second-level ultrasound scan, the diagnosis was probable ovarian cancer with peritoneal Comment carcinomatosis; CA-125 2547 IU/mL. The patient received first-line chemotherapy with carboplatin and paclitaxel every 3 weeks for six Surgery cycles. Concomitant bevacizumab was not admin- istered due to the patient’s history of aortic aneu- rysm. The treatment was complicated by a carbo- platin infusion-related reaction1 during the last cycle, which was resolved pharmacologically with- out requiring hospitalization. The restaging con- trast-enhanced CT scan of the chest and abdomen after the sixth cycle showed complete response. Therefore, the patient was referred to clinical and instrumental follow-up, with a finding of biochemi- cal and radiological progression in the peritoneum approximately 7 months after the end of first-line therapy. – On June 14, 2018: Computed tomography Rationale (CT) scan of the chest and abdomen showed nodules of peritoneal carcinomatosis and sus- In the case of recurrence between 6 and 12 months picious right adnexal mass, no pleural, pulmo- from the last administration of platinum, treatment nary, or hepatic lesions. options are rechallenge with a platinum-based treat- – On June 28, 2018: hysterectomy with bilateral ment or platinum-free therapy with trabectedin + REVIEWS salpingo-oophorectomy, peritoneal washing, PLD combination (Box 1)2. lymphadenectomy, omentectomy, and perito- The choice of treatment at the time of recur- neal biopsies. Residual tumor <1 cm (perito- rence is currently not based solely on
Load more

Recommended publications
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
    cancers Article Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights 1, 1, 1 Adrián Povo-Retana y, Marina Mojena y, Adrian B. Stremtan , Victoria B. Fernández-García 1, Ana Gómez-Sáez 1, Cristina Nuevo-Tapioles 2,3 , José M. Molina-Guijarro 4 , José Avendaño-Ortiz 5, José M. Cuezva 2,3 , Eduardo López-Collazo 5, Juan F. Martínez-Leal 4 and Lisardo Boscá 1,5,6,* 1 Instituto de Investigaciones Biomédicas Alberto Sols (Centro Mixto CSIC-UAM), 28029 Madrid, Spain; [email protected] (A.P.-R.); [email protected] (M.M.); [email protected] (A.B.S.); [email protected] (V.B.F.-G.); [email protected] (A.G.-S.) 2 Centro de Biología Molecular (Centro Mixto CSIC-UAM), Nicolás Cabrera S/N, Ciudad Universitaria de Cantoblanco, 28049 Madrid, Spain; [email protected] (C.N.-T.); [email protected] (J.M.C.) 3 Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), 28029 Madrid, Spain 4 Pharma Mar SA, 28770 Colmenar Viejo, Spain; [email protected] (J.M.M.-G.); [email protected] (J.F.M.-L.) 5 Instituto de Investigación Sanitaria La Paz (IdiPaz), Hospital Universitario La Paz, 28046 Madrid, Spain; [email protected] (J.A.-O.); [email protected] (E.L.-C.) 6 Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-9149-72747 These authors have equal contribution. y Received: 28 August 2020; Accepted: 16 October 2020; Published: 20 October 2020 Simple Summary: Trabectedin and lurbinectedin are two potent onco-therapeutic drugs for the treatment of advanced soft tissue sarcomas.
    [Show full text]
  • To Induce Cytotoxicity of Ovarian Cancer Cells Through Increased Autophagy and Apoptosis
    Endocrine-Related Cancer (2012) 19 711–723 Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis Nan Liu1,2, Sheng Tai2,4, Boxiao Ding2, Ryan K Thor2, Sunita Bhuta2, Yin Sun2 and Jiaoti Huang2,3 1Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong 510515, People’s Republic of China 2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California at Los Angeles, 10833 Le Conte Avenue, 13-229 CHS, Los Angeles, California 90095-1732, USA 3Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine and Stem Cell Biology, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California, USA 4Department of Urology and Anhui Geriatric Institute, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China (Correspondence should be addressed to N Liu at Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University; Email: [email protected]; J Huang at Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California at Los Angeles; Email: [email protected]) Abstract Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway plays a key role in the tumorigenesis of a variety of human cancers including ovarian cancer. However, inhibitors of this pathway such as Rad001 have not shown therapeutic efficacy as a single agent for this cancer. Arsenic trioxide (ATO) induces an autophagic pathway in ovarian carcinoma cells. We found that ATO can synergize with Rad001 to induce cytotoxicity of ovarian cancer cells.
    [Show full text]
  • Thames Valley Chemotherapy Regimens Sarcoma
    Thames Valley Thames Valley Chemotherapy Regimens Sarcoma Chemotherapy Regimens– Sarcoma 1 of 98 Thames Valley Notes from the editor All chemotherapy regimens, and associated guidelines eg antiemetics and dose bands are available on the Network website www.tvscn.nhs.uk/networks/cancer-topics/chemotherapy/ Any correspondence about the regimens should be addressed to: Sally Coutts, Cancer Pharmacist, Thames Valley email: [email protected] Acknowledgements These regimens have been compiled by the Network Pharmacy Group in collaboration with key contribution from Prof Bass Hassan, Medical Oncologist, OUH Dr Sally Trent, Clinical Oncologist, OUH Dr James Gildersleve, Clinical Oncologist, RBFT Dr Sarah Pratap, Medical Oncologist, OUH Dr Shaun Wilson, TYA - Paediatric Oncologist, OUH Catherine Chaytor, Cancer Pharmacist, OUH Varsha Ormerod, Cancer Pharmacist, OUH Kristen Moorhouse, Cancer Pharmacist, OUH © Thames Valley Cancer Network. All rights reserved. Not to be reproduced in whole or in part without the permission of the copyright owner. Chemotherapy Regimens– Sarcoma 2 of 98 Thames Valley Thames Valley Chemotherapy Regimens Sarcoma Network Chemotherapy Regimens used in the management of Sarcoma Date published: January 2019 Date of review: June 2022 Chemotherapy Regimens Name of regimen Indication Page List of amendments to this version 5 Imatinib GIST 6 Sunitinib GIST 9 Regorafenib GIST 11 Paclitaxel weekly (Taxol) Angiosarcoma 13 AC Osteosarcoma 15 Cisplatin Imatinib – if local Trust funding agreed Chordoma 18 Doxorubicin Sarcoma 21
    [Show full text]
  • Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel, Trabectedin and Gemcitabine for Treating Recurrent Ovarian Cancer
    Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer Information for the public Published: TBC nice.org.uk What has NICE said? For recurrent ovarian cancer, the following possible treatments are recommended: paclitaxel (also known as Taxol) on its own or with platinum pegylated liposomal doxorubicin hydrochloride (PLDH, also known as Caelyx) on its own or with platinum. For ovarian cancer that has recurred for the first time and is platinum-sensitive, Nice does not recommend gemcitabine (Gemzar) with carboplatin (Paraplatin), trabectedin (Yondelis) with PLDH, or topotecan (Hycamtin or Potactasol). Topotecan is also not recommended for treating recurrent ovarian cancer that is platinum-resistant or platinum-refractory. What does this mean for me? If you have recurrent ovarian cancer and your doctor thinks that paclitaxel on its own or with platinum, or pegylated liposomal doxorubicin hydrochloride (PLDH) on its own, is the right treatment, you should be able to have the treatment on the NHS. These treatments should be available on the NHS within 3 months of the guidance being issued. © NICE TBC. All rights reserved. Page 1 of 3 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer You may be able to have PLDH with platinum treatment on the NHS as long as your doctor gets your written consent to have it and the NHS within your area agrees to provide it. If you are already taking gemcitabine with carboplatin, trabectedin with PLDH, or topotecan for recurrent ovarian cancer, you should be able to continue taking it until you and your doctor decide it is the right time to stop.
    [Show full text]
  • Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel, Trabectedin and Gemcitabine for Treating Recurrent Ovarian Cancer
    Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer Technology appraisal guidance Published: 26 April 2016 nice.org.uk/guidance/ta389 © NICE 2016. All rights reserved. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389) Contents 1 Recommendations ......................................................................................................................................................... 3 2 The technologies............................................................................................................................................................. 5 Gemcitabine....................................................................................................................................................................................... 5 Paclitaxel ............................................................................................................................................................................................. 5 Pegylated liposomal doxorubicin hydrochloride................................................................................................................. 6 Topotecan............................................................................................................................................................................................ 7 Trabectedin........................................................................................................................................................................................
    [Show full text]
  • YONDELIS (Trabectedin) for Injection, for Intravenous Use  Embryofetal Toxicity: Can Cause Fetal Harm
    Hepatotoxicity: Hepatotoxicity may occur. Monitor and delay and/or HIGHLIGHTS OF PRESCRIBING INFORMATION reduce dose if needed (5.3) These highlights do not include all the information needed to use Cardiomyopathy: Severe and fatal cardiomyopathy can occur. Withhold YONDELIS® safely and effectively. See full prescribing information for YONDELIS in patients with left ventricular dysfunction (5.4) YONDELIS. Capillary leak syndrome: Monitor and discontinue YONDELIS for capillary leak syndrome (5.5) YONDELIS (trabectedin) for injection, for intravenous use Embryofetal toxicity: Can cause fetal harm. Advise of potential risk to a Initial U.S. Approval: 2015 fetus and use effective contraception (5.7, 8.1, 8.3) ----------------------------INDICATIONS AND USAGE---------------------------- ------------------------------ADVERSE REACTIONS------------------------------- YONDELIS is an alkylating drug indicated for the treatment of patients with The most common (≥20%) adverse reactions are nausea, fatigue, vomiting, unresectable or metastatic liposarcoma or leiomyosarcoma who received a constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and prior anthracycline-containing regimen (1) headache. The most common (5%) grades 3-4 laboratory abnormalities are: -----------------------DOSAGE AND ADMINISTRATION----------------------- neutropenia, increased ALT, thrombocytopenia, anemia, increased AST, and Administer at 1.5 mg/m2 body surface area as a 24-hour intravenous increased creatine phosphokinase. (6.1) infusion, every 3 weeks through a central venous line (2.1, 2.5) Premedication: dexamethasone 20 mg intravenously, 30 min before each To report SUSPECTED ADVERSE REACTIONS, contact Janssen infusion (2.2) Biotech, Inc. at 1-800-526-7736 (1-800-JANSSEN) or FDA at 1-800-FDA- Hepatic Impairment: Administer at 0.9 mg/m2 body surface area as a 1088 or www.fda.gov/medwatch.
    [Show full text]
  • Cancer Drugs Used Today
    The American Society of Pharmacognosy Barry R. O’Keefe, Executive Committee American Society of Pharmacognosy Brandcenter, Virginia Commonwealth University, Richmond, VA, September 26, 2014 The American Society of Pharmacognosy Founded in 1959 in Chicago, IL to “promote the growth and development of pharmacognosy, to provide opportunity for association among workers in science, to provide opportunities for presentation of research achievements, and to promote the publication of meritorious research.” The American Society of Pharmacognosy The Premier Society in the United States Devoted to the Study of Natural Products • ASP members have been responsible for the discovery of several of the most important anti-cancer drugs used today. • Almost all of the currently used antibiotics have been derived from natural products. • Natural products are also the templates for antiviral, anti-cholesterol, anti-diabetic, anti-malaria and immunosuppressive agents as well as pain medications. • ASP members are also active in chemical ecology, biodiversity, responsible sourcing and sustainable development of plants, animals, microbes and marine organisms. Why Should You Care About Pharmacognosy? The World’s Forests and Oceans are Rapidly Being Depleted of Unique Species. Natural Products Research and the ASP in Particular Support Biodiversity Efforts Around the Globe. Why Should You Care About Natural Products? >50% of antimicrobial and anti-cancer drugs come from natural products. All Small Molecule Drugs Most large pharmaceutical companies have eliminated
    [Show full text]
  • Relevance of the Fanconi Anemia Pathway in the Response of Human Cells to Trabectedin
    1309 Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin Jose´A. Casado,1 Paula Rı´o,1 Esther Marco,2 human cells to trabectedin reported herein, together with Vero´nica Garcı´a-Herna´ndez,3 Alberto Domingo,3 observations showing the role of the FA pathway in cancer Laura Pe´rez,1,5 Juan Carlos Tercero,5 suppression, strongly suggest that screening for mutations Juan Jose´Vaquero,4 Beatriz Albella,1 in FA genes may facilitate the identification of tumors Federico Gago,2 and Juan A. Bueren1 displaying enhanced sensitivity to this novel anticancer drug. [Mol Cancer Ther 2008;7(5):1309–18] 1Division of Hematopoiesis and Gene Therapy Program, Centro de Investigaciones Energe´ticas, Medioambientales y Tecnolo´gicas and Centro de Investigacio´n Biome´dica en Red de Introduction Enfermedades Raras; Departments of 2Pharmacology, 3Biochemistry and Molecular Biology, and 4Organic Chemistry, Trabectedin (ET-743; Yondelis; Fig. 1A) is a potent Universidad de Alcala´, Alcala´de Henares; and 5PharmaMar S.A., antitumor drug currently undergoing phase II/III clinical Madrid, Spain trials that has recently received regulatory approval from the European Medicines Agency for the treatment of Abstract metastatic or advanced soft-tissue sarcoma after failure to anthracyclines and ifosfamide (1). Trabectedin binds in the Trabectedin (Yondelis; ET-743) is a potent anticancer drug DNA minor groove by establishing a covalent bond with that binds to DNA by forming a covalent bond with a the exocyclic 2-amino group of a guanine in one strand guanine in one strand and one or more hydrogen bonds and one or two hydrogen bonds with other DNA bases in with the opposite strand.
    [Show full text]
  • (Trabectedin) for the Treatment of Soft Tissue Sarcoma
    YONDELIS® (TRABECTEDIN) FOR THE TREATMENT OF SOFT TISSUE SARCOMA PHARMAMAR SINGLE TECHNOLOGY APPRAISAL SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 2ND MARCH 2009 CONTENTS Section A ...................................................................................................... 3 1 Description of technology under assessment .......................................... 3 2 Statement of the decision problem .......................................................... 6 Section B ...................................................................................................... 8 3 Executive summary ................................................................................. 8 4 Context .................................................................................................. 11 5 Equity and equality ................................................................................ 16 6 Clinical evidence .................................................................................... 17 6.1 Identification of studies ...................................................................... 17 6.2 Study selection .................................................................................. 18 6.3 Summary of methodology of relevant RCTs ...................................... 24 6.4 Results of the relevant comparative RCTs ........................................ 36 6.5 Meta-analysis .................................................................................... 43 6.6 Indirect/mixed treatment
    [Show full text]
  • The Antitumor Drugs Trabectedin and Lurbinectedin Induce
    1 The antitumor drugs trabectedin and lurbinectedin induce 2 transcription-dependent replication stress and genome 3 instability 4 5 Emanuela Tumini 1, Emilia Herrera-Moyano 1, Marta San Martín-Alonso 1, 6 Sonia Barroso 1, Carlos M. Galmarini 2 and Andrés Aguilera 1 * 7 8 1 Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, 9 CSIC-Universidad Pablo de Olavide-Universidad de Sevilla, Av. Américo 10 Vespucio 24, 41092 SEVILLE, Spain; 2 PharmaMar, Av. de los Reyes 1, 11 28770 Colmenar Viejo, Spain 12 13 *Corresponding author: Andrés Aguilera, Centro Andaluz de Biología 14 Molecular y Medicina Regenerativa-CABIMER; Av. Américo Vespucio 24, 15 41092 SEVILLE, Spain. Phone: +34 954468372. E-mail: [email protected] 16 17 Running title: ET743 and PM01183 and RNA-dependent DNA damage 18 19 Keywords 20 Trabectedin, lurbinectedin, R-loops, genome instability, cancer 21 22 Conflict of interests statement 23 Dr C.M. Galmarini is an employee and shareholder of PharmaMar. The 24 remaining authors declare no conflict of interest. 25 1 26 ABSTRACT 27 28 R-loops are a major source of replication stress, DNA damage and genome 29 instability, which are major hallmarks of cancer cells. Accordingly, growing 30 evidence suggests that R-loops may also be related to cancer. Here we 31 show that R-loops play an important role in the cellular response to 32 trabectedin (ET743), an anticancer drug from marine origin and its derivative 33 lurbinectedin (PM01183). Trabectedin and lurbinectedin induced RNA-DNA 34 hybrid-dependent DNA damage in HeLa cells, causing replication 35 impairment and genome instability.
    [Show full text]
  • The Activity of Trabectedin As a Single Agent Or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary
    Published OnlineFirst May 27, 2011; DOI: 10.1158/1078-0432.CCR-10-2987 Clinical Cancer Cancer Therapy: Preclinical Research The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary Seiji Mabuchi1, Takeshi Hisamatsu1, Chiaki Kawase1, Masami Hayashi1, Kenjiro Sawada1, Kazuya Mimura1, Kazuhiro Takahashi2, Toshifumi Takahashi2, Hirohisa Kurachi2, and Tadashi Kimura1 Abstract Purpose: The objective of this study was to evaluate the antitumor efficacy of trabectedin in clear cell carcinoma (CCC) of the ovary, which is regarded as an aggressive, chemoresistant, histologic subtype. Experimental Design: Using 6 human ovarian cancer cell lines (3 CCC and 3 serous adenocarcinomas), the antitumor effects of trabectedin were examined in vitro, and we compared its activity according to histology. We next examined the antitumor activity of trabectedin in both cisplatin-resistant and paclitaxel- resistant CCC cells in vitro. Then, the in vivo effects of trabectedin were evaluated using mice inoculated with CCC cell lines. Using 2 pairs of trabectedin-sensitive parental and trabectedin-resistant CCC sublines, we investigated the role of mTOR in the mechanism of acquired resistance to trabectedin. Finally, we determined the effect of mTOR inhibition by everolimus on the antitumor efficacy of trabectedin in vitro and in vivo. Results: Trabectedin showed significant antitumor activity toward chemosensitive and chemoresistant CCC cells in vitro. Mouse xenografts of CCC cells revealed that trabectedin significantly inhibits tumor growth. Greater activation of mTOR was observed in trabectedin-resistant CCC cells than in their respective parental cells. The continuous inhibition of mTOR significantly enhanced the therapeutic efficacy of trabectedin and prevented CCC cells from acquiring resistance to trabectedin.
    [Show full text]